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Abstract
Entamoeba histolytica infects 50 million people per year, causing 100,000 deaths worldwide. The
primary treatment for amoebiasis is metronidazole. However, increased pathogen resistance,
combined with the drug’s toxic side effects encourages a search for alternative therapeutic agents.
Secondary metabolites from marine bacteria are a promising resource for anti-protozoan drug
discovery. In this study, extracts from a collection of marine-derived actinomycetes were screened
for antiamoebic properties and the activities of antibiotics echinomycin A and tirandamycin A are
shown. Both antibiotics inhibited the in vitro growth of a E. histolytica laboratory strain
(HM-1:IMSS) and a clinical isolate (Colombia, Col) at 30 to 60 μM concentrations. EIC50
(estimated inhibitory concentration) values were comparable for both antibiotics (44.3–46.3 μM)
against the E. histolytica clinical isolate.
Keywords
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Introduction
Entamoeba histolytica, the causative agent of amoebic dysentery, is a parasitic contaminant
of food, water, and soil. Upon colonizing the intestine of a primate host, Entamoeba cysts
metamorphose into disease-causing trophozoites. The parasite infects 12% of the world’s
population. Annually, 50 million patients require clinical treatment and up to 100,000 cases
result in mortality (Walsh 1986; Stanley 2003; Haque et al. 2003; Cotruvo et al. 2004,
Ximénez et al. 2009). Approximately 90% of patients with mild to moderate amoebic
symptoms can be treated with metronidazole or other nitroimidazole derivatives. Currently,
luminal amebicides (e.g. diloxanide furoate) are effective on intestinal lumen trophozoites
but not capable to reach tissue ameba (Pritt and Clark 2008; Kenny and Kelly 2009); tissue
amebicides (e.g. metronidazole, dehydroemetine, chloroquine, nitazoxanide) are effective in
the treatment of invasive amebiasis but not able to control luminal trophozoites (Pritt and
Clark 2008; Kenny and Kelly 2009). Close to ninety percent of patients with mild to
moderate amoebic symptoms respond to metronidazole and other nitroimidazole derivatives.
Because of misdiagnoses and asymptomatic carriers (host non-pathogenic E. dispar instead
of the infective E. histolytica) in resource-limited countries, overtreatment with both drugs is
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common (Pritt and Clark 2008). No clinical reports exist on E. histolytica resistance to
metronidazole; however, in vitro metronidazole-resistant E. histolytica strains have been
selected (Wassmann et al. 1999). Resistance in hospital strains of Trichomonas vaginalis,
Giardia lamblia, as well as in anaerobic bacteria (i.e., Clostridium sp., Bacillus fragilis has
been reported (Bendesky et al. 2002; Crowell et al. 2003; Ali and Nozaki 2007). Although
some toxic side effects, neurological, reproductive and potential carcinogenic concerns have
been reported for metronidazole and its derivatives (Bendesky et al. 2002), the strongest
rationale for the search/design of novel antiamebic compounds is a drug that manages both
invasive and luminal amebiasis. Anaerobic pathogens have evolved adaptive metabolic
enzymes that differ from vertebrates, which could be ideal targets of novel drug discovery
and design (Ali and Nozaki 2007).
Secondary metabolites produced by actinobacteria have guided the development of
numerous clinically-used antimicrobial agents (Bérdy 2005). Interestingly, the parent
compound of metronidazole, the nitroimidazole azomycin, was isolated from Streptomyces
eurocidicus in the 1950s (Osato et al. 1955). In addition to their effectiveness as antibacterial
agents, actinomycete metabolites have recently attracted attention as antiparasitic agents. A
screening study of 400 compounds isolated from soil-dwelling microbes revealed the potent
and selective antitrypanosomal activity of ten structurally diverse metabolites (Otoguro et al.
2008). Salinosporamide A, produced by the marine actinomycete Salinispora tropica,
strongly inhibits erythrocytic stages of the of the human malaria parasite Plasmodium
falciparum, perhaps through interactions with the 20S proteasome (Prudhomme et al. 2008)
Protistan grazing poses a significant environmental pressure on marine bacterial
communities, and recent evidence supports that actinobacteria may not be as susceptible to
protists’ attack as other types of bacteria (Fenical and Jensen 2006). Chemical defenses may
be partly responsible for these findings. For example, the bacterial metabolite violacein has
been shown to reduce protozoan grazing (Matz et al. 2004). These findings suggest that new
antiamoebic compounds can be identified from increased investigations of microbial
metabolites. In a search for such agents, we recently undertook a screening of chemical
extracts derived from fermentations of actinomycetes isolated from marine coastal
sediments. Herein we report the isolation and purification of two antibiotics, echinomycin A
and tirandamycin A, and their inhibitory effect on of E. histolytica trophozoites in vitro.
Materials and Methods
All reagents and solvents were purchased from Fisher-Scientific and were analytical grade.
UV spectra were recorded on a DU 800 spectrophotometer (Beckman-Coulter), and IR
spectra were acquired on a Nexus 470 FT-IR (Thermo Nicolet). NMR spectra were recorded
on a Bruker Biospin spectrometer (400 MHz for 1H, 100 MHz for 13C) and were referenced
to residual solvent signals with resonances at 1H/13C = δ 7.24/77.0 (CDCl3). ESI
(electrospray ionization) mass spectrometry was accomplished in 50:50 acetonitrile/water (+
0.1% formic acid) on a Mariner© mass spectrometer (Applied Biosystems). HPLC (high
performance liquid chromatography) was performed using a Waters 600 pump and a 486
tunable absorbance detector using a Waters X-Terra® Prep RP18 column (5 mm 19 × 100
mm).
Marine actinomycete strain collection, cultivation, and biological screening
A library of marine actinomycetes was isolated from marine sediments collected in Fisher’s
Island Sound, New York. Individual strains were isolated using heat shock and desiccation
methods to select for Gram-positive bacteria (Ceri 1999; LaPlante and Rybak 2004; Thelaus
et al. 2008). Pure colonies were isolated on YP marine agar (1g yeast extract, 5 g peptone,
15 g agar per 1 L of synthetic sea water (Instant Ocean; 36 g per L)) supplemented with
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cycloheximide to suppress fungal growth. A total of fifty-five isolates that morphologically
resembled Streptomyces and Micromonospora spp. were individually cultured in 1 L of
yeast-peptone marine media. After approximately 5–8 days of growth, cells were removed
by filtration over Celite, and culture broths were extracted with 500 mL ethyl acetate. The
resulting extracts were stored in DMSO (dimethyl sulfoxide) at -20°C and tested for
inhibition of amoebic growth (Espinosa et al. 2001, 2004, 2009) against E. histolytica
HM-1:1MSS (standard strain; Espinosa et al. 2001, 2004, 2009) and E. histolytica Col
(clinical isolate from a Colombian patient, obtained from NYU, Dan Eichinger laboratory).
The extracts of two Streptomyces strains, isolates URI-F11 and URI-F39, showed inhibitory
activity in an in vitro trophozoite growth assay, and were selected for further chemical
investigation. Strain URI-F11 was isolated from a marine sediment sample collected from a
depth of 12 m in Fisher’s Island Sound, New York (41°17′00″ N, 72° 2′11″ W) and
identified as a Streptomyces sp. by 16S rRNA sequence comparison (deposited with
GenBank as Accession No. JF939719, Socha et al. 2007). Streptomycete strain URI-F39
strain was isolated and identified as previously described (Socha et al. 2009).
Purification and structure identification of tirandamycin A and echinomycin A antibiotics
Strain URI-F11 was cultivated in sixteen 1 L cultures for 7 days at 155 RPM and 24°C in
YP marine broth. The cells were removed by cheesecloth filtration, and the broth was
partitioned between ethyl acetate and H2O. The organic layer was concentrated in vacuo to
yield 800 mg. The extract was separated by flash chromatography using a 20–100% gradient
of methanol in H2O (HP-20-SS Diaion® resin, Supelco). Reversed-phase HPLC of the 80%
methanol fraction using 50–100% acetonitrile in H2O yielded tirandamycin A (9.6 mg).
Tirandamycin was characterized by 1H and 13C NMR spectral comparison to the literature
values (MacKellar et al. 1971). The UV and IR spectra were also identical to the published
values (Meyer 1971; Lee and Rinehart 1980). A molecular weight of 418.2 [M+H]+ 124
confirmed the structure. Echinomycin A was isolated from URI F39 strain as previously
described (The NMR spectra for tirandamycin A and echinomycin A corroborated their
chemical composition, supplementary Fig S1, Socha et al. 2009).
In vitro inhibitory assay
Trophozoites from E. histolytica HM-1:IMSS and E. histolytica Colombia (Col), isolated
from a Colombian patient) were cultured under axenic conditions in flat-bottomed 48-well
plates containing 1.4 ml of Diamond’s TYI-S-33 medium as previously described (Espinosa
et al. 2001, 2004, 2009). Trophozoites in log phase were used in all experiments. Growth
counts were averaged from three replicate wells and three separate experiments. Amoebic
cultures were closely examined to verify absence of bacterial contamination in tubes. To
determine inhibition of E. histolytica growth, standard culture tubes containing an initial
inoculation of 5 × 103 trophozoites were grown for 48 and 72 hrs in TYI-S-33 (alone) or
supplemented with 30 μM echinomycin A, 30 μM tirandamycin A, 60 μM echinomycin A,
or 60 μM tirandamycin A, and counted using a hemocytometer. Metronidazole at a
concentration of 20 μM was used as positive control of inhibition (Espinosa et al. 2001,
2004, 2009). All test compounds were dissolved in DMSO; a similar volume of DMSO was
added to control wells of ameba (data not shown) to discard toxicity due to the solvent.
Results
The growth inhibitory properties of pure echinomycin A (Fig 1A) and tirandamycin A (Fig
1B) were measured against E. histolytica HM-1:IMSS (Espinosa et al. 2001, 2004, 2009)
and E. histolytica Col. The latter is a clinical isolate derived from a Colombian patient
(obtained from NYU, Dan Eichinger laboratory). Each compound inhibited the growth of
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both E. histolytica strains at 30 and 60 μM concentrations (Figs 2, 3). A 60 μM
concentration of echinomycin A inhibited 71.1% and 67.6% of trophozoites, respectively
(Fig 2, Table 1). A 60 μM treatment with tirandamycin A resulted in a slightly stronger
inhibition, demonstrating a 84.2% reduction in growth of E. histolytica HM-1:IMSS and
64.8% reduction in growth by E. histolytica Col (Fig 3, Table 1). EIC50 values were
comparable for both antibiotics (44.3–46.3 μM) against E. histolytica Col (Table 1). EIC50
is defined as the estimated inhibitory concentrations of drug required to inhibit 50% amoebic
growth.
Discussion
Secondary metabolites produced by marine actinomycetes represent a promising resource
for anti-parasitic drug discovery (Bérdy, 2005; Fenical and Jensen 2006; Otoguro et al.
2008; Prudhomme et al. 2008). This is the first investigation of actinomycete metabolites in
the context of amoebic infections. An intial testing of extracts from a panel of 55 marine
actinomycetes revealed the antiamoebic activity of echinomycin A and tirandamycin A
against E. histolytica.
Echinomycin A is a potent antitumor and antibacterial agent that exerts its activity via DNA
bisintercalation (Waring and Wakelin 1974). As such, echinomycin A has been shown to
inhibit vertebrate DNA replication, chromatin decondensation, and transcription (May et al.
2004). The antiamoebic activity of echinomycin A could be due to the fact that amoeba are
highly metabolic cells, which replicate 2–3 times per day (Ong and Wolfson, 1970; Austin
and Warren 1983). Echinomycin has been tested in mice against methicillin-resistant
Staphylococus aureus (MRSA) peritoneal infections and shown an ED50 of 0.5–1.3 mg/kg
with little toxicity (Park et al. 2008).
Tirandamycin A inhibits chain initiation and elongation of bacterial RNA polymerase
without acting on mammalian polymerases (Reusser 1976). Three tirandamycins isolated
from Streptomyces sp. 17944 inhibited the parasitic nematode Brugia malayi at 30 μM
concentrations (Yu et al. 2011). The antibiotics affected the Asparagine tRNA synthetase,
which suggests that the mechanism of action in E. histolytica could be through affecting
RNA associated enzymes.
As compared to echinomycin A and tirandamycin A, metronidazole is a more potent
inhibitor of tropozoite growth. However, toxic side effects and increasing metronidazole
resistance by parasitic microbes (Bendesky, 2002; Crowell 2003; Haque et al. 2003; Ali and
Nozaki 2007) limit it clinical use. These results suggest that both echinomycin A and
tirandamycin A could be pursued as alternative treatments for amoebiasis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
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Figure 2.
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Figure 3.
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